Ethics committees and research in Italy: seeking new regulatory frameworks (with a look at the past) by Petrini, Carlo & Brusaferro, Silvio
C
o
m
m
e
n
t
a
r
y
314
Ann Ist Super Sanità 2019 | Vol. 55, No. 4: 314-318
DOI: 10.4415/ANN_19_04_02
Commentary
Ethics committees and research in Italy:
seeking new regulatory frameworks  
(with a look at the past)
Carlo Petrini1 and Silvio Brusaferro2
1Unità di Bioetica, Istituto Superiore di Sanità, Rome, Italy 
2President, Istituto Superiore di Sanità, Rome, Italy
A LOOK AT THE PAST
The story of ethics committees (ECs) in Italy is at a 
watershed point, because of a number of factors.
Certain factors result from new technical and scien-
tific advances, others from new legislative requirements.
In terms of new technical and scientific advances, 
these include a range of possibilities, including digital 
therapies, the increasing interconnections between de-
vices and medicines, and advanced therapies. Technical 
and scientific advances are also reflected in new meth-
ods and new designs for clinical trials, such as adaptive 
studies or decentralised clinical trials.
New technical and scientific advances are not the 
subject of this commentary, which relates, rather, to a 
discussion of certain considerations associated with the 
regulatory environment, and in particular in terms of 
the organisation and functioning of ECs.
The regulatory picture is changing both within the 
European Union and domestically.
In the European Union, a new era began with the ap-
plication of Regulation (EU) No 536/2014 on clinical 
trials on medicinal products [1] and Regulation (EU) 
No 2017/745 on medical devices [2]. Both will be in 
force from 2020: Regulation (EU) No 536/2014, as es-
tablished in Article 99, will apply from six months after 
the publication of a notice (referred to in Article 82(3)) 
regarding the full functionality of a portal and a data-
base containing the data and the information about the 
trials, while Regulation (EU) No 2017/745, as estab-
lished in Article 123, will apply from 26 May 2020.
In Italy, Articles 1 and 2 of Law No 3 of 11 Janu-
ary 2018 [3] introduce important changes in the proce-
dures for the authorisation of clinical trials on medicinal 
products for human use.
To view the problem appropriately, a brief historical 
review of the organisation of ECs in Italy might be valu-
able.
In the 1980s, there were few bodies in Italy that could 
be classified as ECs (regionally, in public bodies and in 
universities).
The first legislative text took the form of the Ministe-
rial Decree of 27 April 1992, Provisions on the technical 
documentation to be submitted in support of applications for 
marketing authorisations for proprietary medicinal products 
for human use, in implementation of Directive 91/507/EEC 
[4]. Article 2 of that text stipulates as follows: “Where 
they are created in Italy, ethics committees, which must 
comply in all cases with the requirements of good clini-
cal practice (…), must be established within medical or 
scientific bodies of proven reliability”.
A more precise physiognomy was laid down in 1997, 
with the Decree of 15 July 1997, Transposition of the EC 
good clinical practice guidelines for clinical trials on medici-
nal products [5]. In Article 4 (“Establishment of ethics 
committees and reference committees”), paragraph 1 
establishes that “Independent ethics committees for 
the evaluation of the clinical trials on medicinal prod-
ucts shall be established according to the information 
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laid down and in compliance with the minimum require-
ments stated in paragraph 3 of Annex 1 to this Decree”. 
Various operating requirements are listed in that Annex.
However, a precise framework for the establishment 
of ECs was only enacted in 1998, in the Decree of 18 
March 1998, Reference guidelines for the establishment and 
functioning of ethics committees [6]. Article 1(1)(1) of An-
nex 1 to that Decree defines an EC as “an independent 
body, created within a medical or scientific research in-
stitution according to interdisciplinary criteria”.
The following year, Legislative Decree No 299 of 19 
June 1999, Provisions intended to rationalise the Italian 
national health service, in accordance with Article 1 of Law 
No 419 of 30 November 1998 [7], created an “Ethics 
Committee for Research and Clinical Trials” nationally, 
with the composition of that body governed by the De-
cree of 23 November 1999, Composition and determina-
tion of the functions of the National Ethics Committee for 
Clinical Trials on Medicinal Products, in accordance with 
Legislative Decree No 299 of 19 June 1999 [8]. However, 
that national committee never became operational.
A fundamental step for clinical regulation in Italy was 
achieved, following the adoption of Directive 2001/20/
EC [9], through Legislative Decree No 211 of 24 June 
2003, Implementation of Directive 2001/20/EC on the 
implementation of good clinical practice in the conduct of 
clinical trials on medicinal products for clinical use [10]. 
Article 2(1)(m) establishes that an EC is “an indepen-
dent body consisting of healthcare professionals and 
non-medical members, whose responsibility it is to pro-
tect the rights, safety and wellbeing of human subjects 
involved in a trial and to provide public assurance of 
that protection […]”.
In the last two years of the previous century and the 
first two years of the current one, ECs were therefore 
created in each Italian region within hospitals, univer-
sity polyclinics and biomedical research bodies and in-
stitutions.
A new regulatory framework was then introduced 
through Law No 189 of 8 November 2012, Conversion 
into law, with amendments, of Decree-Law No 158 of 13 
September 2012, on urgent provisions to promote the devel-
opment of the country by providing a higher degree of health 
protection [11]. In Article 12 (“Procedure concerning 
medicinal products”), paragraph 10 establishes that 
“by 30 June 2013, each of the regions and the autono-
mous provinces of Trento and Bolzano shall restructure 
the ethics committees existing within its territory” and 
states, under subparagraph c, that “The jurisdiction of 
each committee may extend, in addition to clinical trials 
on medicinal products, to any other question relating to 
the use of medicinal products and medical devices, the 
use of surgical and clinical procedures or the study of 
food products on humans generally referred, per inter-
national practice, for assessment by such committees”.
On the basis of that law, the Decree of 8 February 
2013, Criteria governing the composition and functioning of 
ethics committees [12], was then enacted. In Article 1 of 
that Decree (“Definitions and functions of ethics com-
mittees”), paragraph 1 states that “Ethics committees 
(…) shall be independent bodies (…) that have the re-
sponsibility of guaranteeing the protection of the rights, 
safety and wellbeing of persons involved in trials and 
of providing public assurance of that protection” and 
paragraph 2 states that “Where these are not already 
attributed to specific bodies, ethics committees may 
also perform consultative functions in relation to ethi-
cal questions associated with scientific and healthcare 
activities, in order to protect and promote the dignity 
of the individual. Ethics committees may also propose 
initiatives for training of healthcare professionals in re-
lation to the sphere of bioethics”. This Decree resulted 
in a substantial reduction in the number of ECs in Italy: 
from 243 in 2012, this figure fell to 91 in 2014 and is 
currently 90 [13]).
The following year saw the adoption of the above-
mentioned Regulation (EU) No 536/2014 [1]. The 
principal implications of that Regulation have already 
been discussed in this journal [14].
Article 8 of the Regulation (“Decision on the clinical 
trial”) states that “Each Member State concerned shall 
notify the sponsor through the EU portal as to whether 
the clinical trial is authorised, whether it is authorised 
subject to conditions, or whether authorisation is re-
fused. Notification shall be done by way of one single 
decision”. The need to express a “single decision” na-
tionally stimulated the debate on the reduction in the 
number of ECs. There were numerous suggestions: 
there were those who proposed that all assessments 
of clinical trials conducted in Italy be centralised in a 
single National Ethics Committee, those who proposed 
the creation of a national institution subdivided into 
sections corresponding to therapeutic areas, those who 
suggested establishing a dozen committees, those who 
proposed assigning a committee to each region, and 
those with other ideas [15, 16].
THE PRESENT AND THE FUTURE
Law No 3 of 11 January 2018 [3] provides for a fur-
ther reduction in the number of ECs: indeed, on the 
basis of Article 2(7), within 60 days following the entry 
into force of the Law (15 February 2018), a decree en-
acted by the Minister of Health was to (…) “identify a 
maximum of 40 local ethics committees” and, on the 
basis of paragraph 9, a decree enacted by the Minis-
ter of Health within the same period “[was to identify] 
a maximum of three national ethics committees, with 
one reserved for trials in a paediatric environment”. The 
difficulty inherent in implementing this reform of Ital-
ian ECs is demonstrated by the fact that the decrees 
creating the local ECs and the national ECs have still 
not been enacted.
Legislative Decree No 52 of 14 May 2019, Implemen-
tation of the delegated powers to review and reform the regu-
latory provisions in relation to clinical trials on medicinal 
products for human use, under Article 1(1) and (2) of Law 
No 3 of 11 January 2018 [17], implemented certain of 
the delegated powers for the Government established 
under Article 1 of Law No 3 of 11 January 2018. Cer-
tain provisions contained in the Decree could have a 
significant impact. In particular, in order to gain value 
from non-profit clinical trials, even those with limited 
intervention, sponsors are permitted to transfer the 
corresponding data and results of the trial for regis-
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tration purposes. Until now, the use of data obtained 
from non-profit trials for registration purposes was not 
permitted. With the new text, in the case that these 
data and results are used for registration purposes, the 
sponsor or transferee is required to pay and reimburse 
the direct and indirect costs associated with the trial, 
and, following potential reclassification of the study as 
profit-making, to pay the corresponding charges, in-
cluding any revenues resulting from the exploitation 
of intellectual property. On this point, a Decree of the 
Minister of Health to be enacted by 31 October 2019 
is required to stipulate measures intended to facilitate 
and support the performance of non-profit clinical trials 
and observational studies and to identify the methods 
for coordination between public and private sponsors 
in the same clinical trial or clinical study, including for 
the purpose of acquiring information following market 
introduction of the medicinal products. That Decree 
also introduced criteria for identifying the types of and 
requirements for non-profit trials and trials with coop-
eration between public and private sponsors, and for 
governing the methods for transferring data relating to 
trials to the sponsor and the use of those data for reg-
istration purposes. The Decree also establishes that an 
order enacted by the AIFA will identify the appropriate 
methods for protecting the independence of the clinical 
trial and guaranteeing the absence of conflicts of inter-
est in assessment of corresponding requests.
We can see from the above that this moment is cru-
cial. And it is important to consider some factors that 
are relevant for the choices and decisions that the leg-
islators and the Italian Government will need to make:
• the full implementation of Regulation (EU) No 
536/2014 [1] requires that the organisation of ECs 
and the methods used to assess requests for authorisa-
tion of new clinical trials must be efficient: if Italy is 
not attractive in this sector, it will remain marginalised;
• the identification of 40 local ECs is particularly dif-
ficult because this would involve a halving of the 
current number. The decision was made to reduce 
the number [3] in order to optimise the sector and 
improve efficiency. However, the elimination of ap-
proximately 50% of ECs would also involve a loss of 
valuable expertise, and a substantial workload for the 
40 recognised ECs. If there is still an intention to re-
duce the number of ECs, the committees that will 
not be authorised for assessment of clinical trials un-
der Regulation (EU) No 536/2014 [1] could still be 
used to assess studies other than clinical trials (such 
as observational studies, studies on biological mate-
rial of human origin, compassionate use, etc.). The 
ECs authorised to assess clinical trials will in fact be 
overworked, and will find it difficult to find the time 
for studies other than clinical trials;
• the National Centre for Coordination of Ethics 
Committees (“National Centre for the Coordination 
of Regional Ethics Committees for Clinical Trials of 
Medicines and Medical Devices for Human Use”), 
created [18] under Article 2 of Law No 3 of 11 Janu-
ary 2018 [3] must be structured appropriately (in 
terms of allocated resources, location, composition) 
to enable it to perform its role. This fact was recog-
nised by the Ministry of Health in the “Document on 
pharmaceutical governance” [19]. A bill on reforming 
the Coordination Centre has been tabled before the 
Chamber of Deputies [20];
• non-profit clinical trials must be promoted and ap-
propriately supported, including in financial terms;
• the legal requirements governing observational stud-
ies (which currently cover only studies involving the 
administration of medicinal products [21-23]) must 
be amended, establishing streamlined, efficient au-
thorisation processes for the many types of observa-
tional studies in which non medicinal products are 
administered;
• the management of conflicts of interest must be sub-
ject to rules that are rigorous but do not suffocate 
relationships (including in the form of public-private 
partnerships), which are essential for the efficiency of 
research. Article 6(4) of Legislative Decree No 52 of 
14 May 2019 [17] establishes that “in order to pro-
tect the independence and impartiality of the clini-
cal trial, the investigator shall declare in advance to 
the institution within which the clinical study is be-
ing performed that, in relation to the proposed study, 
there are no financial interests held by his/her spouse 
or partner or relations up to the second degree in the 
capital of the pharmaceutical company owning the 
drug covered by the study, and he/she has no employ-
ment, consultancy or cooperative relationships, for 
any purpose, with the sponsor”. It is clear that this 
provision is excessively restrictive: research is devel-
oped through cooperation (including private-public 
partnerships). Requiring “no employment, consul-
tancy or cooperative relationships, for any purpose” 
imposes a serious obstacle to the development of 
research. That obstacle should be removed, and it is 
to be hoped that the measure to be adopted by the 
AIFA, under Article 6(1) of that Legislative Decree 
[17], in accordance with paragraph 4, will identify 
criteria that not only do not suffocate but actually 
promote research;
• biological material of human origin is a resource with 
enormous potential for biomedical research, and we 
need rules that enable its efficient use. Legislative 
Decree No 52 of 14 May 2019 [17] has entrusted 
the Italian National Institute of Health (Istituto Su-
periore di Sanità) (“with the support of the European 
Biobanking and Biomolecular Resources Research 
Infrastructure (BBMRI)”) with the task of drafting 
address lines “for the use for research purposes of 
biological or clinical material remaining from previ-
ous diagnostic or therapeutic activities or held for 
any other purpose”. The Italian National Institute of 
Health has created a corresponding working group 
made up of representatives of the Research Coordi-
nation and Support Centre and the Bioethics Unit 
from that body. This group is tasked with developing 
address lines to promote a sector that has seen con-
siderable development and is destined to play a cru-
cial role in biomedical research in the coming years;
• to make Italy attractive for companies performing 
clinical trials, we need to adopt a system of charg-
es for ECs that is competitive with other Member 
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States of the European Union. Article 2 of Law No 
3 of 11 January 2018 [3] envisages the adoption of 
a decree by the Minister of Health, in conjunction 
with the Minister of Economic Affairs and Finance, 
for the “determination of a single fee for clinical tri-
als”. That decree has not yet been adopted. Currently, 
the charges for ECs are established by regional de-
cisions. In multicentre studies, a payment must be 
made to the EC for each participating centre (each 
of which has, inter alia, at least partially, specific rules 
for submission of requests). Innovative choices have 
been made within the European Union. For example, 
in France the charges for ECs have been abolished 
(by the Financial Law No 1425/2008 [24]) and Spain 
established an effective network of ECs since 2015 
[25]. Italy cannot allow itself to remain marginalised 
in a sector that, if appropriately promoted, is a source 
of a great deal of investment.
Italy has a long and competitive history in biomedical 
research. ECs’ role is crucial for this process and all ef-
forts to provide clear rules and efficiency should be put 
in place. Nevertheless, ECs are part of the challenge and 
a comprehensive global approach to biomedical research 
should be considered a national priority. This include 
both privacy issues, administrative rules, supply chain 
contracts, researcher status, etc. Setting up standard 
processes where rules and timing are clearly defined and 
guaranteed is a crucial challenge for the future of the bio-
medical research In Italy.
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